Last reviewed · How we verify

bupivacaine S50:R50 plus 8% glucose

Cristália Produtos Químicos Farmacêuticos Ltda. · Phase 3 active Small molecule

bupivacaine S50:R50 plus 8% glucose is a Local anesthetic Small molecule drug developed by Cristália Produtos Químicos Farmacêuticos Ltda.. It is currently in Phase 3 development for Spinal anesthesia for surgical procedures, Regional anesthesia for pain management.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Spinal anesthesia for surgical procedures, Regional anesthesia for pain management.

At a glance

Generic namebupivacaine S50:R50 plus 8% glucose
SponsorCristália Produtos Químicos Farmacêuticos Ltda.
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhasePhase 3

Mechanism of action

Bupivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and transmission of pain signals. The S50:R50 racemic mixture combined with 8% glucose creates a hyperbaric spinal anesthetic solution suitable for regional anesthesia. The glucose increases the specific gravity of the solution, allowing controlled spread within the cerebrospinal fluid.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bupivacaine S50:R50 plus 8% glucose

What is bupivacaine S50:R50 plus 8% glucose?

bupivacaine S50:R50 plus 8% glucose is a Local anesthetic drug developed by Cristália Produtos Químicos Farmacêuticos Ltda., indicated for Spinal anesthesia for surgical procedures, Regional anesthesia for pain management.

How does bupivacaine S50:R50 plus 8% glucose work?

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

What is bupivacaine S50:R50 plus 8% glucose used for?

bupivacaine S50:R50 plus 8% glucose is indicated for Spinal anesthesia for surgical procedures, Regional anesthesia for pain management.

Who makes bupivacaine S50:R50 plus 8% glucose?

bupivacaine S50:R50 plus 8% glucose is developed by Cristália Produtos Químicos Farmacêuticos Ltda. (see full Cristália Produtos Químicos Farmacêuticos Ltda. pipeline at /company/crist-lia-produtos-qu-micos-farmac-uticos-ltda).

What drug class is bupivacaine S50:R50 plus 8% glucose in?

bupivacaine S50:R50 plus 8% glucose belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is bupivacaine S50:R50 plus 8% glucose in?

bupivacaine S50:R50 plus 8% glucose is in Phase 3.

What are the side effects of bupivacaine S50:R50 plus 8% glucose?

Common side effects of bupivacaine S50:R50 plus 8% glucose include Hypotension, Bradycardia, Headache (post-dural puncture), Neurological toxicity (at high doses), Cardiovascular toxicity (at high doses).

What does bupivacaine S50:R50 plus 8% glucose target?

bupivacaine S50:R50 plus 8% glucose targets Voltage-gated sodium channels and is a Local anesthetic.

Related